Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Transcriptomic analysis of CFTR-impaired endothelial cells reveals a pro-inflammatory phenotype

Mathias Declercq, Pauline de Zeeuw, Nadine Vasconcelos Conchinha, Vincent Geldhof, Anabela S. Ramalho, Melissa García-Caballero, Katleen Brepoels, Marjolein Ensinck, Marianne S. Carlon, Matthew J. Bird, Stefan Vinckier, Marijke Proesmans, François Vermeulen, Lieven Dupont, Bart Ghesquière, Mieke Dewerchin, Peter Carmeliet, David Cassiman, Lucas Treps, Guy Eelen, Peter Witters
European Respiratory Journal 2020; DOI: 10.1183/13993003.00261-2020
Mathias Declercq
1Department of Development and Regeneration, CF Centre, Woman and Child, KU Leuven, Leuven, Belgium
2Laboratory of Angiogenesis and Vascular Metabolism, Centre for Cancer Biology, VIB, Leuven, Belgium
3Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology and Leuven Cancer Institute (LKI), KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mathias Declercq
Pauline de Zeeuw
2Laboratory of Angiogenesis and Vascular Metabolism, Centre for Cancer Biology, VIB, Leuven, Belgium
3Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology and Leuven Cancer Institute (LKI), KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadine Vasconcelos Conchinha
2Laboratory of Angiogenesis and Vascular Metabolism, Centre for Cancer Biology, VIB, Leuven, Belgium
3Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology and Leuven Cancer Institute (LKI), KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Geldhof
2Laboratory of Angiogenesis and Vascular Metabolism, Centre for Cancer Biology, VIB, Leuven, Belgium
3Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology and Leuven Cancer Institute (LKI), KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anabela S. Ramalho
4Stem Cell and Developmental Biology, CF Centre, Woman and Child, KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa García-Caballero
2Laboratory of Angiogenesis and Vascular Metabolism, Centre for Cancer Biology, VIB, Leuven, Belgium
3Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology and Leuven Cancer Institute (LKI), KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katleen Brepoels
2Laboratory of Angiogenesis and Vascular Metabolism, Centre for Cancer Biology, VIB, Leuven, Belgium
3Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology and Leuven Cancer Institute (LKI), KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marjolein Ensinck
5Laboratory for Molecular Virology and Drug Discovery, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianne S. Carlon
5Laboratory for Molecular Virology and Drug Discovery, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew J. Bird
6Laboratory of Hepatology, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium
7Metabolomics Expertise Centre, Centre for Cancer Biology, VIB, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Vinckier
2Laboratory of Angiogenesis and Vascular Metabolism, Centre for Cancer Biology, VIB, Leuven, Belgium
3Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology and Leuven Cancer Institute (LKI), KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marijke Proesmans
8Department of Paediatrics, University Hospitals Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Vermeulen
9Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lieven Dupont
10Department of Pneumology, University Hospitals Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bart Ghesquière
7Metabolomics Expertise Centre, Centre for Cancer Biology, VIB, Leuven, Belgium
11Metabolomics Expertise Centre, Department of Oncology, KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mieke Dewerchin
2Laboratory of Angiogenesis and Vascular Metabolism, Centre for Cancer Biology, VIB, Leuven, Belgium
3Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology and Leuven Cancer Institute (LKI), KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Carmeliet
2Laboratory of Angiogenesis and Vascular Metabolism, Centre for Cancer Biology, VIB, Leuven, Belgium
3Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology and Leuven Cancer Institute (LKI), KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Cassiman
6Laboratory of Hepatology, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium
12Centre of Metabolic Diseases, University Hospitals Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucas Treps
2Laboratory of Angiogenesis and Vascular Metabolism, Centre for Cancer Biology, VIB, Leuven, Belgium
3Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology and Leuven Cancer Institute (LKI), KU Leuven, Leuven, Belgium
13equal co-authorship;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guy Eelen
2Laboratory of Angiogenesis and Vascular Metabolism, Centre for Cancer Biology, VIB, Leuven, Belgium
3Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology and Leuven Cancer Institute (LKI), KU Leuven, Leuven, Belgium
13equal co-authorship;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Witters
1Department of Development and Regeneration, CF Centre, Woman and Child, KU Leuven, Leuven, Belgium
8Department of Paediatrics, University Hospitals Leuven, Leuven, Belgium
12Centre of Metabolic Diseases, University Hospitals Leuven, Leuven, Belgium
13equal co-authorship;
14co-corresponding author
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Cystic fibrosis (CF) is a life-threatening disorder characterised by decreased pulmonary mucociliary and pathogen clearance, and an exaggerated inflammatory response leading to progressive lung damage. CF is caused by bi-allelic pathogenic variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene which encodes a chloride channel. CFTR is expressed in endothelial cells (ECs) and EC dysfunction has been reported in CF patients, but a role for this ion channel in CF disease progression is poorly described.

We used an unbiased RNA sequencing approach in complementary models of CFTR silencing and blockade (by the CFTR inhibitor CFTRinh-(172)) in human ECs to characterise the changes upon CFTR impairment. Key findings were further validated in vitro, in vivo in CFTR knock-out mice and ex vivo in CF patient-derived ECs.

Both models of CFTR impairment revealed that EC proliferation, migration and autophagy were downregulated. Remarkably though, defective CFTR function led to EC activation and a persisting pro-inflammatory state of the endothelium with increased leukocyte adhesion. Further validation in CFTR knock-out mice revealed enhanced leukocyte extravasation in lung and liver parenchyma associated with increased levels of EC activation markers. In addition, CF patient-derived ECs displayed increased EC activation markers and leukocyte adhesion, which was partially rescued by using CFTR modulators VX770-VX809.

Our integrated analysis thus suggests that ECs are no innocent bystanders in CF pathology, but rather may contribute to the exaggerated inflammatory phenotype, raising the question whether normalisation of vascular inflammation might be a novel therapeutic strategy to ameliorate the disease severity of CF.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Yan reports grants from National Institutes of Health, during the conduct of the study;.

Conflict of interest: Dr. Declercq has nothing to disclose.

Conflict of interest: Dr. de Zeeuw has nothing to disclose.

Conflict of interest: Nadine Conchinha has nothing to disclose.

Conflict of interest: Dr. Geldhof has nothing to disclose.

Conflict of interest: Dr. Ramalho has nothing to disclose.

Conflict of interest: Dr. García-Caballero has nothing to disclose.

Conflict of interest: Dr. Brepoels has nothing to disclose.

Conflict of interest: Dr. Ensinck has nothing to disclose.

Conflict of interest: Dr. Carlon has nothing to disclose.

Conflict of interest: Dr. Bird has nothing to disclose.

Conflict of interest: Dr. Vinckier has nothing to disclose.

Conflict of interest: Dr. Proesmans has nothing to disclose.

Conflict of interest: Dr. Vermeulen has nothing to disclose.

Conflict of interest: Dr. Dupont has nothing to disclose.

Conflict of interest: Dr. Ghesquière has nothing to disclose.

Conflict of interest: Dr. Eelen has nothing to disclose.

Conflict of interest: Dr. Dewerchin has nothing to disclose.

Conflict of interest: Dr. Carmeliet has nothing to disclose.

Conflict of interest: Dr. Cassiman has nothing to disclose.

Conflict of interest: Dr. Treps has nothing to disclose.

Conflict of interest: Dr. Witters has nothing to disclose.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Received February 7, 2020.
  • Accepted October 4, 2020.
  • Copyright ©ERS 2020
PreviousNext
Back to top
View this article with LENS
Vol 59 Issue 6 Table of Contents
European Respiratory Journal: 59 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Transcriptomic analysis of CFTR-impaired endothelial cells reveals a pro-inflammatory phenotype
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Transcriptomic analysis of CFTR-impaired endothelial cells reveals a pro-inflammatory phenotype
Mathias Declercq, Pauline de Zeeuw, Nadine Vasconcelos Conchinha, Vincent Geldhof, Anabela S. Ramalho, Melissa García-Caballero, Katleen Brepoels, Marjolein Ensinck, Marianne S. Carlon, Matthew J. Bird, Stefan Vinckier, Marijke Proesmans, François Vermeulen, Lieven Dupont, Bart Ghesquière, Mieke Dewerchin, Peter Carmeliet, David Cassiman, Lucas Treps, Guy Eelen, Peter Witters
European Respiratory Journal Jan 2020, 2000261; DOI: 10.1183/13993003.00261-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Transcriptomic analysis of CFTR-impaired endothelial cells reveals a pro-inflammatory phenotype
Mathias Declercq, Pauline de Zeeuw, Nadine Vasconcelos Conchinha, Vincent Geldhof, Anabela S. Ramalho, Melissa García-Caballero, Katleen Brepoels, Marjolein Ensinck, Marianne S. Carlon, Matthew J. Bird, Stefan Vinckier, Marijke Proesmans, François Vermeulen, Lieven Dupont, Bart Ghesquière, Mieke Dewerchin, Peter Carmeliet, David Cassiman, Lucas Treps, Guy Eelen, Peter Witters
European Respiratory Journal Jan 2020, 2000261; DOI: 10.1183/13993003.00261-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF

Subjects

  • Lung biology and experimental studies
  • CF and non-CF bronchiectasis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung volumes and survival in chronic lung allograft dysfunction
  • StO2 during weaning from mechanical ventilation
  • Automated quantification of radiological patterns predicts IPF survival
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society